Sequencing the SARS-CoV-2 Genome from Stool Samples of Post-acute Cases Implicates a Novel Mutation Associated with Reduced Antibody Neutralization



Abstract Views
206

Downloads
9

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Mar 2, 2023
Published Jul 13, 2023
10.24018/ejbiomed.2023.2.3.66

Abstract viewed = 206 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Whole-genome SARS-CoV-2 sequencing tools are crucial for tracking the COVID-19 pandemic. However, current techniques require sampling of actively infectious patients following COVID-19 testing to recover enough SARS-CoV-2 RNA from the nasopharyngeal passage, which rapidly clears during the first few weeks of infection. A prospective assessment of the viral genome sourced from recovered non-infectious patients would greatly facilitate epidemiological tracking. Thus, we developed a protocol to isolate and sequence the genome of SARS-CoV-2 from stool samples of post-acute SARS-CoV-2 patients, at timepoints ranging from 10-120 days after onset of symptoms. Stool samples were collected from patients at varying timepoints post-convalescence, and viral DNA was isolated and sequenced using the QIAamp Viral RNA Mini Kit (Qiagen Inc.) and Ion Ampliseq™ Library Kit Plus (Life Technologies Corporation). Capacity of neutralizing antibodies in patient plasma was tested using a Luminex panel (Coronavirus Ig Total Human 11-Plex ProcartaPlex™ Panel, ThermoFisher). Of 64 samples obtained from post-acute patients, 21 (32.8%) yielded sufficient material for whole-genome sequencing. This allowed us to identify widely divergent phylogenetic relativity of the SARS-CoV-2 genome from post-acute patients living in the same households and infected around the same time. Additionally, we observed that individuals who recovered from infection expressed varying degrees of antibodies against SARS-CoV-2 structural proteins that corresponded to distinct variants. Interestingly, we identified a novel point mutation in the viral genome where infected patients expressed antibodies with a significantly reduced capacity to neutralize the virus in vitro relative to that of those infected with the wild-type strain. Altogether, we demonstrate a protocol to successfully sequence the SARS-CoV-2 genome from stool samples from patients up to 4 months post-infection, which can be applied to studies that assess the relationship between variants and immune response post-hoc and safe monitoring of the SARS-CoV-2 genome during the pandemic.

Keywords: COVID-19 sequencing stool variants

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.
    DOI  |   Google Scholar
  2. Johns Hopkins Coronavirus Resource Center. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. 2022 [cited 2022 Feb 4]. Available from: https://coronavirus.jhu.edu/map.html
     Google Scholar
  3. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020 Jul;24:91–8.
    DOI  |   Google Scholar
  4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–3.
    DOI  |   Google Scholar
  5. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141–54.
    DOI  |   Google Scholar
  6. Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):904–8.
    DOI  |   Google Scholar
  7. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003 Nov 27;426(6965):450–4.
    DOI  |   Google Scholar
  8. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 May 12;323(18):1843–4.
    DOI  |   Google Scholar
  9. Peng L, Liu J, Xu W, Luo Q, Chen D, Lei Z, et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. J Med Virol. 2020 Sep;92(9):1676–80.
    DOI  |   Google Scholar
  10. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020 Apr 28;9(1):45.
    DOI  |   Google Scholar
  11. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020 Nov 1;5(11):1281–5.
    DOI  |   Google Scholar
  12. Shen Q, Xiao X, Aierken A, Yue W, Wu X, Liao M, et al. The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. J Cell Mol Med. 2020 Aug;24(16):9472–7.
    DOI  |   Google Scholar
  13. Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. Cells. 2020 Apr 9;9(4):E920.
    DOI  |   Google Scholar
  14. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020 May 14;181(4):905-913.e7.
    DOI  |   Google Scholar
  15. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020 Oct;11(10):771–5.
    DOI  |   Google Scholar
  16. Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020 Jul 3;369(6499):50–4.
    DOI  |   Google Scholar
  17. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020 Jun;69(6):997–1001.
    DOI  |   Google Scholar
  18. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3.
    DOI  |   Google Scholar
  19. Xiao F, Wan P, Wei Q, Wei G, Yu Y. Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: A case report and literature overview. J Med Virol. 2022 Jul;94(7):3133–7.
    DOI  |   Google Scholar
  20. Gupta S, Parker J, Smits S, Underwood J, Dolwani S. Persistent viral shedding of SARS‐CoV‐2 in faeces – a rapid review. Colorectal Dis. 2020 Jun 4;10.1111/codi.15138.
    DOI  |   Google Scholar
  21. Pereira NL, Ahmad F, Byku M, Cummins NW, Morris AA, Owens A, et al. COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clin Proc. 2021 Feb;96(2):446–63.
    DOI  |   Google Scholar
  22. Bavelaar HHJ, Rahamat-Langendoen J, Niesters HGM, Zoll J, Melchers WJG. Whole genome sequencing of fecal samples as a tool for the diagnosis and genetic characterization of norovirus. Journal of Clinical Virology. 2015 Nov 1;72:122–5.
    DOI  |   Google Scholar
  23. Deng L, Silins R, Castro-Mejía JL, Kot W, Jessen L, Thorsen J, et al. A Protocol for Extraction of Infective Viromes Suitable for Metagenomics Sequencing from Low Volume Fecal Samples. Viruses. 2019 Jul;11(7):667.
    DOI  |   Google Scholar
  24. Khalifeh A, Blumstein DT, Fontenele RS, Schmidlin K, Richet C, Kraberger S, et al. Diverse cressdnaviruses and an anellovirus identified in the fecal samples of yellow-bellied marmots. Virology. 2021 Feb 1;554:89–96.
    DOI  |   Google Scholar
  25. Strubbia S, Phan MVT, Schaeffer J, Koopmans M, Cotten M, Le Guyader FS. Characterization of Norovirus and Other Human Enteric Viruses in Sewage and Stool Samples Through Next-Generation Sequencing. Food Environ Virol. 2019 Dec 1;11(4):400–9.
    DOI  |   Google Scholar
  26. Cerrada-Romero C, Berastegui-Cabrera J, Camacho-Martínez P, Goikoetxea-Aguirre J, Pérez-Palacios P, Santibáñez S, et al. Excretion and viability of SARS-CoV-2 in feces and its association with the clinical outcome of COVID-19. Sci Rep. 2022 May 5;12(1):7397.
    DOI  |   Google Scholar
  27. Kipkorir V, Cheruiyot I, Ngure B, Misiani M, Munguti J. Prolonged SARS-CoV-2 RNA detection in anal/rectal swabs and stool specimens in COVID-19 patients after negative conversion in nasopharyngeal RT-PCR test. Journal of Medical Virology. 2020;92(11):2328–31.
    DOI  |   Google Scholar
  28. Xu Y, Kang L, Shen Z, Li X, Wu W, Ma W, et al. Dynamics of severe acute respiratory syndrome coronavirus 2 genome variants in the feces during convalescence. Journal of Genetics and Genomics. 2020 Oct 20;47(10):610–7.
    DOI  |   Google Scholar
  29. Mardian Y, Kosasih H, Karyana M, Neal A, Lau CY. Review of Current COVID-19 Diagnostics and Opportunities for Further Development. Front Med (Lausanne). 2021;8:615099.
    DOI  |   Google Scholar
  30. Mohan SV, Hemalatha M, Kopperi H, Ranjith I, Kumar AK. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges. Chem Eng J. 2021 Feb 1;405:126893.
    DOI  |   Google Scholar
  31. Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 May 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK570580/
     Google Scholar
  32. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 Jun 10;384(23):2212–8.
    DOI  |   Google Scholar
  33. Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021 Jun;13(6):317–25.
    DOI  |   Google Scholar
  34. Bakhshandeh B, Sorboni SG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, et al. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol. 2021 Jun;90:104773.
    DOI  |   Google Scholar
  35. Fricke-Galindo I, Falfán-Valencia R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review. Front Immunol. 2021 Apr 1;12:622176.
    DOI  |   Google Scholar
  36. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021 Feb;76(2):428–55.
    DOI  |   Google Scholar
  37. Kim S, Jazwinski SM. The Gut Microbiota and Healthy Aging: A Mini-Review. Gerontology. 2018;64(6):513–20.
    DOI  |   Google Scholar
  38. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021 Feb;37(2):e3377.
    DOI  |   Google Scholar